Next Article in Journal
The Elevated Pre-Treatment C-Reactive Protein Predicts Poor Prognosis in Patients with Locally Advanced Rectal Cancer Treated with Neo-Adjuvant Radiochemotherapy
Next Article in Special Issue
Coexistence of Growth Hormone Deficiency and Pituitary Microadenoma in a Child with Unique Mosaic Turner Syndrome: A Case Report and Literature Review
Previous Article in Journal
Diagnostic Ability of Radiofrequency Ultrasound in Parkinson’s Disease Compared to Conventional Transcranial Sonography and Magnetic Resonance Imaging
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 10
Issue 10
10.3390/diagnostics10100779
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic Aspects

by
Yasmin Tatour
and
Tamar Ben-Yosef
*
Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(10), 779; https://doi.org/10.3390/diagnostics10100779
Submission received: 9 September 2020 / Revised: 30 September 2020 / Accepted: 1 October 2020 / Published: 2 October 2020
(This article belongs to the Special Issue Genetic Testing for Rare Diseases)
Browse Figures
Versions Notes

Abstract

:
Inherited retinal diseases (IRDs), which are among the most common genetic diseases in humans, define a clinically and genetically heterogeneous group of disorders. Over 80 forms of syndromic IRDs have been described. Approximately 200 genes are associated with these syndromes. The majority of syndromic IRDs are recessively inherited and rare. Many, although not all, syndromic IRDs can be classified into one of two major disease groups: inborn errors of metabolism and ciliopathies. Besides the retina, the systems and organs most commonly involved in syndromic IRDs are the central nervous system, ophthalmic extra-retinal tissues, ear, skeleton, kidney and the cardiovascular system. Due to the high degree of phenotypic variability and phenotypic overlap found in syndromic IRDs, correct diagnosis based on phenotypic features alone may be challenging and sometimes misleading. Therefore, genetic testing has become the benchmark for the diagnosis and management of patients with these conditions, as it complements the clinical findings and facilitates an accurate clinical diagnosis and treatment.

Graphical Abstract

1. Introduction

The retina is a multi-layered sensory tissue that lines the back of the eye. Its main function is the transduction of light energy into an electrical potential change, via a process known as phototransduction. The light-sensitive elements of the retina are the photoreceptor cells. The retina contains two types of photoreceptors, rods and cones. Rods (approximately 120 million in the human eye) are in charge of night vision, while cones (6 to 7 million in the human eye) are in charge of visual acuity and color vision. The highest cone concentration is found in the central region of the retina, known as the macula. Photoreceptors are highly compartmentalized cells, with the nucleus and other cellular organs located in the inner segment (IS), while the entire phototransduction machinery is included in the outer segment (OS).
Inherited retinal diseases (IRDs), which are among the most common genetic diseases in humans, define a clinically heterogeneous group of disorders, which cause visual loss due to improper development, dysfunction or premature death of the retinal photoreceptors [1]. IRDs are distinguished by several factors, including the type and location of affected cells and the timing of disease onset. The most common form of IRD is retinitis pigmentosa (RP) (also known as rod–cone dystrophy) [2]. Other IRD forms include cone/cone–rod dystrophy (CD/CRD) [3]; Leber congenital amaurosis (LCA) [4]; macular dystrophy (MD); and achromatopsia (rod monochromatism) [5], among others.
IRD is also one of the most genetically heterogeneous groups of disorders in humans, with over 260 genes identified to date (RetNet at https://sph.uth.edu/retnet/). It can be inherited as autosomal recessive (AR), autosomal dominant (AD) or X-linked (XL). Mitochondrial and digenic modes of inheritance have also been described. While in most cases of IRD the disease is limited to the eye (non-syndromic), over 80 forms of syndromic IRD have been described. Approximately 200 genes are associated with these syndromes (Table 1). In some cases of syndromic IRD, the retinal disease may be the presenting symptom and other systemic findings evolve during childhood, puberty or later on in life. In other cases, the first identifiable symptom of the syndrome is non-ocular and the retinal phenotype is revealed only later in life.
The topic of systemic diseases associated with IRDs has been reviewed before, including the description of some of these syndromes [6]. In the current review, we provide a comprehensive summary of the vast majority of syndromic IRD forms reported to date, for which the underlying gene/s have been identified (as listed in OMIM-Online Mendelian Inheritance in Man, https://www.ncbi.nlm.nih.gov/omim, and reported in the literature). We discuss different aspects, including the marked genetic heterogeneity of some of these syndromes, phenotypic overlap and diagnostic approaches.

2. Syndromic IRD Types

The majority of syndromic IRDs are recessively inherited and rare. Many, although not all, syndromic IRDs can be classified into one of two major disease groups: inborn errors of metabolism (IEM) and ciliopathies.
IEMs are genetic disorders leading to failure of carbohydrate metabolism, protein metabolism, fatty acid oxidation or glycogen storage. Many IEMs present with neurologic symptoms [9]. The retina develops from an embryonic forebrain pouch and is considered an extension of the brain. Therefore, neurodegeneration resulting from IEMs often involves retinal degeneration (RD) as well. Major forms of syndromic IRD that belong to the IEM group include congenital disorders of glycosylation (CDG) [10], neuronal ceroid lipofuscinoses (CLNs) [11], mucopolysaccharidoses (MPSs) [12], peroxisomal diseases [13] and more (Table 1).
Ciliopathies are a group of genetic diseases caused by mutations in genes associated with the structure and function of primary cilia. Primary cilia function as signaling hubs that sense environmental cues and are pivotal for organ development and function, and for tissue homeostasis. By their nature, cilia defects are usually pleiotropic, affecting more than one system [14]. Photoreceptor OSs are highly modified primary sensory cilia. The proximal end of the OS is linked to the cell body (i.e., the IS) via a connecting cilium which is structurally homologous to the transition zone of primary cilia [15]. Consequently, retinal pathogenesis is a common finding in ciliopathies. Other organs which are commonly affected in ciliopathies are the central nervous system (CNS), kidney, liver, skeleton and inner ear. Major forms of syndromic IRD that belong to the ciliopathy group include Bardet–Biedl Syndrome (BBS) [16], Joubert Syndrome (JBTS) [17], Usher Syndrome (USH) [18], Senior–Løken Syndrome (SLN) [19] and Alstrom Syndrome (ALMS) [20] (Table 1).

3. Genetic Heterogeneity in Syndromic IRDs

Over 80 forms of syndromic IRD have been described (Table 1). Most of these syndromes are caused by a single gene. However, 14 of 81 (17%) of the syndromes listed in Table 1 are genetically heterogeneous, and some of them are associated with multiple causative genes. The most genetically heterogeneous forms of syndromic IRD are three recessively inherited ciliopathies: BBS, JBTS and USH. The protein products of the genes associated with each one of these ciliopathies tend to form multi-protein complexes in the retina and in additional tissues, thus explaining the similar phenotypes caused by mutations in each of these genes.
BBS (prevalence of about 1/125,000) is characterized by a combination of RP, postaxial polydactyly (and other skeletal abnormalities), hypogonadism, renal disease, intellectual disability (ID) and truncal obesity [16]. Twenty-one causative genes have been reported to date (OMIM) (Table 1). Their protein products are involved in lipid homeostasis, intraflagellar transport, establishing planar cell polarity, regulation of intracellular trafficking and centrosomal functions. Eight of these genes encode for subunits of a protein complex, the BBSome, which is integral in ciliary as well as intracellular trafficking [21]. In the retina, the BBSome is required for photoreceptor OS formation and maintenance [22], as well as for retinal synaptogenesis [23].
JBTS (prevalence of 1/55,000–1/200,000) is characterized by a peculiar midbrain–hindbrain malformation, known as the molar tooth sign. The neurological presentation of JBTS includes hypotonia that evolves into ataxia, developmental delay, abnormal eye movements and neonatal breathing abnormalities. This picture is often associated with variable multiorgan involvement, mainly of the retina, kidney and liver [17]. RD has been reported in 38% of patients [24]. To date, 36 causative genes have been identified, all encoding for proteins expressed in the primary cilium or its apparatus (OMIM). Mutations in 20 of these genes (listed in Table 1) have been specifically associated with RD and additional ocular abnormalities (such as nystagmus and oculomotor apraxia). Ocular abnormalities have also been reported in patients with mutations in most other JBTS genes. However, since RD was not specifically reported in these patients, these genes are not listed in Table 1. Given the marked phenotypic heterogeneity found in JBTS patients, it is very likely that a retinal phenotype will be associated with these genes in the future, as additional patients are discovered.
USH (prevalence of 1–4/25,000) is characterized by the combination of RP and sensorineural hearing loss (HL). Based on the severity and progression of HL, age at onset of RP and the presence or absence of vestibular impairment, the majority of USH cases can be classified into one of three clinical subtypes (USH1-3). Eleven USH genes have been identified to date (OMIM) (Table 1). Their protein products are associated with a wide range of functions, including actin-binding molecular motors, cell adhesion, scaffolding and cellular trafficking. USH proteins form complexes and function cooperatively in neurosensory cells of both the retina and the inner ear (reviewed in [18,25]).

4. Phenotypic Overlap in Syndromic IRDs

When referring to syndromic IRD, phenotypic overlap is a common phenomenon, which can be divided into three groups, as detailed below:

4.1. Phenotypic Overlap between Different IRD Syndromes

Many types of syndromic IRD have a multi-systemic nature. Certain organs are commonly involved in syndromic IRDs. Specifically, CNS involvement (usually manifested as ID) is found in 68% of IRD syndromes (Table 1 and Figure 1), and over 80 genes are associated with the combination of IRD and ID [26] (Table 1). In addition to ID, the most common findings in syndromic IRD are extra-retinal eye abnormalities and ear, skeletal, renal and cardiovascular involvement (Figure 1). Most of these syndromes are phenotypically heterogeneous, with many patients exhibiting only some of the phenotypic features. These factors lead to a marked phenotypic overlap between different syndromes, and to a diagnostic challenge. For example, the combination of RD, ID, renal disease and skeletal abnormalities is found in numerous forms of syndromic IRD, including BBS, JBTS and ALMS, among others (Table 1). The combination of retinal abnormalities and HL as prominent symptoms is found in USH, as well as in CRD and HL 1 syndrome [27], Leber congenital amaurosis with early-onset deafness syndrome [28], Norrie disease [29], peroxisome biogenesis disorders, Refsum disease [30] and more (Table 1). These overlaps may often lead to diagnostic mistakes [27,31,32].

4.2. Syndromic Versus Non-Syndromic IRD Caused by the Same Genes

Twenty-eight of the genes listed in Table 1 can cause both syndromic and non-syndromic IRD (Table 2 and Figure 2). In general, milder hypomorphic mutations in these genes are associated with non-syndromic IRD, while null mutations lead to the involvement of additional tissues. In addition, the involvement of additional genetic and environmental factors in the determination of the final phenotypic outcome cannot be excluded. A prominent example is the USH2A gene. Mutations in this gene are the most common cause of USH, and specifically of USH2 (RP with congenital, mild to moderate sensorineural HL) [33]. Moreover, USH2A variants are also one of the commonest causes of AR non-syndromic RP worldwide [34,35,36]. It appears that the specific combination of USH2A variants determines whether one has USH2 or non-syndromic RP [37,38,39]. In addition, RD is more severe in patients with USH2A-related USH2 than in patients with USH2A-related non-syndromic RP. However, the reason is not completely understood [38].

4.3. Co-Existence of Non-Syndromic IRD and Additional Non-Ocular Diseases

IRD is one of the most genetically heterogeneous groups of disorders in humans, and most cases of IRD are non-syndromic. Non-syndromic IRD may coincide with other genetic (and non-genetic) rare conditions, leading to a clinical suspicion or diagnosis of a syndrome. For example, co-occurrence of non-syndromic RP and non-syndromic HL in a family may appear as USH [71].

5. Diagnostic Challenges

Due to the high degree of phenotypic variability and phenotypic overlap found in syndromic IRD, as described above, correct diagnosis based on phenotypic features alone may be challenging and sometimes misleading. Therefore, genetic testing has become the benchmark for the diagnosis and management of patients with these conditions, as it complements the clinical findings and facilitates an accurate clinical diagnosis. Establishing a correct diagnosis is important for both the patients and their family members, for multiple reasons: it enables the understanding of the natural history course, and the prediction of disease prognosis; it aids in tailoring correct follow-up and treatment, including potential gene-targeted therapies [72]; it leads to a reduction in disease prevalence, by genetic screening and counseling in high-risk populations; it allows the patients to pursue prenatal counseling and reproductive planning; and it enables identification of novel disease genes and mechanisms.
The existence of common founder mutations in certain populations allows for quick and efficient mutation screening in affected individuals, based on the relevant phenotype and ethnic background. This is performed by PCR-based DNA amplification and Sanger sequencing, or by specifically designed assays. Some examples are common USH3A-, USH1F-, ML4- and BBS2-causative mutations found in the Ashkenazi Jewish population [73,74,75,76]; and USH3A- and MKS1-causative mutations found in the Finnish population [77,78]. Nevertheless, for most syndromic IRD patients worldwide, this strategy is not effective.
Currently, the most efficient approach for genetic diagnosis in monogenic diseases, including IRDs, is next-generation sequencing (NGS). NGS technologies facilitate the screening of the entire genome (whole genome sequencing, WGS); of all protein-coding regions (whole exome sequencing, WES); or of protein-coding regions of pre-determined panels of genes (targeted NGS, T-NGS) [79,80]. Since protein-coding regions comprise only 1–2% of the entire genome while harboring over 85% of variants causing Mendelian disorders, WES is still considered as the method of choice for genetic analysis, in both clinical and research settings. However, worldwide diagnostic yields of IRD patients by WES only range between 60% and 70% [36,81,82]. The missing mutations can be divided into four groups: (1) mutations located within exons, but missed due to technical issues, e.g., lack of coverage; (2) mutations located within covered exons, but missed due to limitations in data analysis and interpretation; (3) non-coding variants that may affect gene expression, mRNA stability, splicing and more; and (4) structural variants, such as large deletions, duplications and inversions, which are missed by WES. The latter two may be identified by WGS [34].

6. Summary and Conclusions

Over 80 forms of syndromic IRDs have been described, and approximately 200 causative genes identified. Due to the high degree of phenotypic variability and phenotypic overlap found in syndromic IRD, correct diagnosis based on phenotypic features alone is insufficient, and genetic testing has become the benchmark for the diagnosis and management of patients with these conditions. For most patients, molecular diagnosis should be based on NGS technologies. Currently, WES is the most popular approach for genetic analysis in patients with monogenic diseases, including IRDs. However, the continuous progress in both technical and bioinformatic aspects, as well as the reduction of costs, is already leading to a shift towards WGS as the method of choice.

Author Contributions

Conceptualization, T.B.-Y.; methodology, T.B.-Y.; validation, Y.T. and T.B.-Y.; formal analysis, Y.T.; investigation, Y.T. and T.B.-Y.; resources, T.B.-Y.; data curation, Y.T. and T.B.-Y.; writing—original draft preparation, T.B.-Y.; writing—review and editing, T.B.-Y.; supervision, T.B.-Y.; funding acquisition, T.B.-Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Israel Science Foundation (grant number 525/19).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Duncan, J.L.; Pierce, E.A.; Laster, A.M.; Daiger, S.P.; Birch, D.G.; Ash, J.D.; Iannaccone, A.; Flannery, J.G.; Sahel, J.A.; Zack, D.J.; et al. Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. Transl. Vis. Sci. Technol. 2018, 7, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Verbakel, S.K.; van Huet, R.A.C.; Boon, C.J.F.; den Hollander, A.I.; Collin, R.W.J.; Klaver, C.C.W.; Hoyng, C.B.; Roepman, R.; Klevering, B.J. Non-syndromic retinitis pigmentosa. Prog. Retin. Eye Res. 2018, 66, 157–186. [Google Scholar] [CrossRef] [PubMed]
  3. Thiadens, A.A.; Phan, T.M.; Zekveld-Vroon, R.C.; Leroy, B.P.; van den Born, L.I.; Hoyng, C.B.; Klaver, C.C.; Roosing, S.; Pott, J.W.; van Schooneveld, M.J.; et al. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy. Ophthalmology 2012, 119, 819–826. [Google Scholar] [CrossRef] [PubMed]
  4. Kumaran, N.; Moore, A.T.; Weleber, R.G.; Michaelides, M. Leber congenital amaurosis/early-onset severe retinal dystrophy: Clinical features, molecular genetics and therapeutic interventions. Br. J. Ophthalmol. 2017, 101, 1147–1154. [Google Scholar] [CrossRef] [PubMed]
  5. Tsang, S.H.; Sharma, T. Rod Monochromatism (Achromatopsia). Adv. Exp. Med. Biol. 2018, 1085, 119–123. [Google Scholar]
  6. Werdich, X.Q.; Place, E.M.; Pierce, E.A. Systemic diseases associated with retinal dystrophies. Semin. Ophthalmol. 2014, 29, 319–328. [Google Scholar] [CrossRef]
  7. Shamseldin, H.E.; Shaheen, R.; Ewida, N.; Bubshait, D.K.; Alkuraya, H.; Almardawi, E.; Howaidi, A.; Sabr, Y.; Abdalla, E.M.; Alfaifi, A.Y.; et al. The morbid genome of ciliopathies: An update. Genet. Med. 2020, 22, 1051–1060. [Google Scholar] [CrossRef]
  8. Iwama, K.; Takaori, T.; Fukushima, A.; Tohyama, J.; Ishiyama, A.; Ohba, C.; Mitsuhashi, S.; Miyatake, S.; Takata, A.; Miyake, N.; et al. Novel recessive mutations in MSTO1 cause cerebellar atrophy with pigmentary retinopathy. J. Hum. Genet. 2018, 63, 263–270. [Google Scholar] [CrossRef]
  9. Ferreira, C.R.; van Karnebeek, C.D.M. Inborn errors of metabolism. Handb. Clin. Neurol. 2019, 162, 449–481. [Google Scholar]
  10. Freeze, H.H.; Schachter, H.; Kinoshita, T. Genetic Disorders of Glycosylation. In Essentials of Glycobiology, 3rd ed.; Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., et al., Eds.; Cold Spring Harbor Laboratory Press: New York, NY, USA, 2017; Chapter 45. [Google Scholar]
  11. Nita, D.A.; Mole, S.E.; Minassian, B.A. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016, 18, 73–88. [Google Scholar] [CrossRef]
  12. Muenzer, J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50 (Suppl. 5), v4–v12. [Google Scholar] [CrossRef] [Green Version]
  13. Imanaka, T. Biogenesis and Function of Peroxisomes in Human Disease with a Focus on the ABC Transporter. Biol. Pharm. Bull. 2019, 42, 649–665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Sreekumar, V.; Norris, D.P. Cilia and development. Curr. Opin. Genet. Dev. 2019, 56, 15–21. [Google Scholar] [CrossRef] [PubMed]
  15. May-Simera, H.; Nagel-Wolfrum, K.; Wolfrum, U. Cilia—The sensory antennae in the eye. Prog. Retin. Eye Res. 2017, 60, 144–180. [Google Scholar] [CrossRef]
  16. Tsang, S.H.; Aycinena, A.R.P.; Sharma, T. Ciliopathy: Bardet-Biedl Syndrome. Adv. Exp. Med. Biol. 2018, 1085, 171–174. [Google Scholar] [PubMed]
  17. Valente, E.M.; Dallapiccola, B.; Bertini, E. Joubert syndrome and related disorders. Handb. Clin. Neurol. 2013, 113, 1879–1888. [Google Scholar] [PubMed]
  18. Geleoc, G.G.S.; El-Amraoui, A. Disease mechanisms and gene therapy for Usher syndrome. Hear. Res. 2020, 394, 107932. [Google Scholar] [CrossRef] [PubMed]
  19. Tsang, S.H.; Aycinena, A.R.P.; Sharma, T. Ciliopathy: Senior-Loken Syndrome. Adv. Exp. Med. Biol. 2018, 1085, 175–178. [Google Scholar] [PubMed]
  20. Tsang, S.H.; Aycinena, A.R.P.; Sharma, T. Ciliopathy: Alstrom Syndrome. Adv. Exp. Med. Biol. 2018, 1085, 179–180. [Google Scholar] [PubMed]
  21. Petriman, N.A.; Lorentzen, E. Moving proteins along in the cilium. Elife 2020, 9, e55254. [Google Scholar] [CrossRef]
  22. Hsu, Y.; Garrison, J.E.; Kim, G.; Schmitz, A.R.; Searby, C.C.; Zhang, Q.; Datta, P.; Nishimura, D.Y.; Seo, S.; Sheffield, V.C. BBSome function is required for both the morphogenesis and maintenance of the photoreceptor outer segment. PLoS Genet. 2017, 13, e1007057. [Google Scholar] [CrossRef]
  23. Hsu, Y.; Garrison, J.E.; Seo, S.; Sheffield, V.C. The absence of BBSome function decreases synaptogenesis and causes ectopic synapse formation in the retina. Sci. Rep. 2020, 10, 8321. [Google Scholar] [CrossRef]
  24. Wang, S.F.; Kowal, T.J.; Ning, K.; Koo, E.B.; Wu, A.Y.; Mahajan, V.B.; Sun, Y. Review of Ocular Manifestations of Joubert Syndrome. Genes 2018, 9, 605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. El-Amraoui, A.; Petit, C. The retinal phenotype of Usher syndrome: Pathophysiological insights from animal models. Comptes Rendus Biol. 2014, 337, 167–177. [Google Scholar] [CrossRef] [PubMed]
  26. Yang, X.R.; Benson, M.D.; MacDonald, I.M.; Innes, A.M. A diagnostic approach to syndromic retinal dystrophies with intellectual disability. Am. J. Med. Genet. C Semin. Med. Genet. 2020, 184, 538–570. [Google Scholar] [CrossRef] [PubMed]
  27. Namburi, P.; Ratnapriya, R.; Khateb, S.; Lazar, C.H.; Kinarty, Y.; Obolensky, A.; Erdinest, I.; Marks-Ohana, D.; Pras, E.; Ben-Yosef, T.; et al. Bi-allelic Truncating Mutations in CEP78, Encoding Centrosomal Protein 78, Cause Cone-Rod Degeneration with Sensorineural Hearing Loss. Am. J. Hum. Genet. 2016, 99, 777–784. [Google Scholar] [CrossRef] [Green Version]
  28. Luscan, R.; Mechaussier, S.; Paul, A.; Tian, G.; Gerard, X.; Defoort-Dellhemmes, S.; Loundon, N.; Audo, I.; Bonnin, S.; LeGargasson, J.F.; et al. Mutations in TUBB4B Cause a Distinctive Sensorineural Disease. Am. J. Hum. Genet. 2017, 101, 1006–1012. [Google Scholar] [CrossRef] [Green Version]
  29. Sims, K.B. NDP-Related Retinopathies. In GeneReviews®; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2014. [Google Scholar]
  30. Tsang, S.H.; Sharma, T. Inborn Errors of Metabolism: Refsum Disease. Adv. Exp. Med. Biol. 2018, 1085, 191–192. [Google Scholar]
  31. Raas-Rothschild, A.; Wanders, R.J.; Mooijer, P.A.; Gootjes, J.; Waterham, H.R.; Gutman, A.; Suzuki, Y.; Shimozawa, N.; Kondo, N.; Eshel, G.; et al. A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents. Am. J. Hum. Genet. 2002, 70, 1062–1068. [Google Scholar] [CrossRef] [Green Version]
  32. Smith, C.E.; Poulter, J.A.; Levin, A.V.; Capasso, J.E.; Price, S.; Ben-Yosef, T.; Sharony, R.; Newman, W.G.; Shore, R.C.; Brookes, S.J.; et al. Spectrum of PEX1 and PEX6 variants in Heimler syndrome. Eur. J. Hum. Genet. 2016, 24, 1565–1571. [Google Scholar] [CrossRef]
  33. Le Quesne Stabej, P.; Saihan, Z.; Rangesh, N.; Steele-Stallard, H.B.; Ambrose, J.; Coffey, A.; Emmerson, J.; Haralambous, E.; Hughes, Y.; Steel, K.P.; et al. Comprehensive sequence analysis of nine Usher syndrome genes in the UK National Collaborative Usher Study. J. Med. Genet. 2012, 49, 27–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Carss, K.J.; Arno, G.; Erwood, M.; Stephens, J.; Sanchis-Juan, A.; Hull, S.; Megy, K.; Grozeva, D.; Dewhurst, E.; Malka, S.; et al. Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. Am. J. Hum. Genet. 2017, 100, 75–90. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Dockery, A.; Stephenson, K.; Keegan, D.; Wynne, N.; Silvestri, G.; Humphries, P.; Kenna, P.F.; Carrigan, M.; Farrar, G.J. Target 5000: Target Capture Sequencing for Inherited Retinal Degenerations. Genes 2017, 8, 304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Sharon, D.; Ben-Yosef, T.; Goldenberg-Cohen, N.; Pras, E.; Gradstein, L.; Soudry, S.; Mezer, E.; Zur, D.; Abbasi, A.H.; Zeitz, C.; et al. A nationwide genetic analysis of inherited retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC). Hum. Mutat. 2019, 41, 140–149. [Google Scholar] [CrossRef] [PubMed]
  37. Lenassi, E.; Vincent, A.; Li, Z.; Saihan, Z.; Coffey, A.J.; Steele-Stallard, H.B.; Moore, A.T.; Steel, K.P.; Luxon, L.M.; Heon, E.; et al. A detailed clinical and molecular survey of subjects with nonsyndromic USH2A retinopathy reveals an allelic hierarchy of disease-causing variants. Eur. J. Hum. Genet. 2015, 23, 1318–1327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Pierrache, L.H.; Hartel, B.P.; van Wijk, E.; Meester-Smoor, M.A.; Cremers, F.P.; de Baere, E.; de Zaeytijd, J.; van Schooneveld, M.J.; Cremers, C.W.; Dagnelie, G.; et al. Visual Prognosis in USH2A-Associated Retinitis Pigmentosa Is Worse for Patients with Usher Syndrome Type IIa Than for Those with Nonsyndromic Retinitis Pigmentosa. Ophthalmology 2016, 123, 1151–1160. [Google Scholar] [CrossRef] [PubMed]
  39. Sengillo, J.D.; Cabral, T.; Schuerch, K.; Duong, J.; Lee, W.; Boudreault, K.; Xu, Y.; Justus, S.; Sparrow, J.R.; Mahajan, V.B.; et al. Electroretinography Reveals Difference in Cone Function between Syndromic and Nonsyndromic USH2A Patients. Sci. Rep. 2017, 7, 11170. [Google Scholar] [CrossRef]
  40. Nishiguchi, K.M.; Avila-Fernandez, A.; van Huet, R.A.; Corton, M.; Perez-Carro, R.; Martin-Garrido, E.; Lopez-Molina, M.I.; Blanco-Kelly, F.; Hoefsloot, L.H.; van Zelst-Stams, W.A.; et al. Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: From syndromic to nonsyndromic retinal degeneration. Ophthalmology 2014, 121, 1620–1627. [Google Scholar] [CrossRef]
  41. Nguyen, T.T.; Hull, S.; Roepman, R.; van den Born, L.I.; Oud, M.M.; de Vrieze, E.; Hetterschijt, L.; Letteboer, S.J.F.; van Beersum, S.E.C.; Blokland, E.A.; et al. Missense mutations in the WD40 domain of AHI1 cause non-syndromic retinitis pigmentosa. J. Med. Genet. 2017, 54, 624–632. [Google Scholar] [CrossRef]
  42. Aldrees, A.; Abdelkader, E.; Al-Habboubi, H.; Alrwebah, H.; Rahbeeni, Z.; Schatz, P. Non-syndromic retinal dystrophy associated with homozygous mutations in the ALMS1 gene. Ophthalmic Genet. 2019, 40, 77–79. [Google Scholar] [CrossRef]
  43. Audo, I.; El Shamieh, S.; Mejecase, C.; Michiels, C.; Demontant, V.; Antonio, A.; Condroyer, C.; Boyard, F.; Letexier, M.; Saraiva, J.P.; et al. ARL2BP mutations account for 0.1% of autosomal recessive rod-cone dystrophies with the report of a novel splice variant. Clin. Genet. 2017, 92, 109–111. [Google Scholar] [PubMed]
  44. Davidson, A.E.; Schwarz, N.; Zelinger, L.; Stern-Schneider, G.; Shoemark, A.; Spitzbarth, B.; Gross, M.; Laxer, U.; Sosna, J.; Sergouniotis, P.I.; et al. Mutations in ARL2BP, encoding ADP-ribosylation-factor-like 2 binding protein, cause autosomal-recessive retinitis pigmentosa. Am. J. Hum. Genet. 2013, 93, 321–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Holtan, J.P.; Teigen, K.; Aukrust, I.; Bragadottir, R.; Houge, G. Dominant ARL3-related retinitis pigmentosa. Ophthalmic Genet. 2019, 40, 124–128. [Google Scholar] [CrossRef] [PubMed]
  46. Aldahmesh, M.A.; Safieh, L.A.; Alkuraya, H.; Al-Rajhi, A.; Shamseldin, H.; Hashem, M.; Alzahrani, F.; Khan, A.O.; Alqahtani, F.; Rahbeeni, Z.; et al. Molecular characterization of retinitis pigmentosa in Saudi Arabia. Mol. Vis. 2009, 15, 2464–2469. [Google Scholar]
  47. Shevach, E.; Ali, M.; Mizrahi-Meissonnier, L.; McKibbin, M.; El-Asrag, M.; Watson, C.M.; Inglehearn, C.F.; Ben-Yosef, T.; Blumenfeld, A.; Jalas, C.; et al. Association Between Missense Mutations in the BBS2 Gene and Nonsyndromic Retinitis Pigmentosa. JAMA Ophthalmol. 2015, 133, 312–318. [Google Scholar] [CrossRef] [Green Version]
  48. Khan, A.O.; Decker, E.; Bachmann, N.; Bolz, H.J.; Bergmann, C. C8orf37 is mutated in Bardet-Biedl syndrome and constitutes a locus allelic to non-syndromic retinal dystrophies. Ophthalmic Genet. 2016, 37, 290–293. [Google Scholar] [CrossRef]
  49. Mejecase, C.; Hummel, A.; Mohand-Said, S.; Andrieu, C.; El Shamieh, S.; Antonio, A.; Condroyer, C.; Boyard, F.; Foussard, M.; Blanchard, S.; et al. Whole exome sequencing resolves complex phenotype and identifies CC2D2A mutations underlying non-syndromic rod-cone dystrophy. Clin. Genet. 2019, 95, 329–333. [Google Scholar] [CrossRef]
  50. den Hollander, A.I.; Koenekoop, R.K.; Yzer, S.; Lopez, I.; Arends, M.L.; Voesenek, K.E.; Zonneveld, M.N.; Strom, T.M.; Meitinger, T.; Brunner, H.G.; et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am. J. Hum. Genet. 2006, 79, 556–561. [Google Scholar] [CrossRef] [Green Version]
  51. Khan, A.O.; Eisenberger, T.; Nagel-Wolfrum, K.; Wolfrum, U.; Bolz, H.J. C21orf2 is mutated in recessive early-onset retinal dystrophy with macular staphyloma and encodes a protein that localises to the photoreceptor primary cilium. Br. J. Ophthalmol. 2015, 99, 1725–1731. [Google Scholar] [CrossRef]
  52. Suga, A.; Mizota, A.; Kato, M.; Kuniyoshi, K.; Yoshitake, K.; Sultan, W.; Yamazaki, M.; Shimomura, Y.; Ikeo, K.; Tsunoda, K.; et al. Identification of Novel Mutations in the LRR-Cap Domain of C21orf2 in Japanese Patients With Retinitis Pigmentosa and Cone-Rod Dystrophy. Investig. Ophthalmol. Vis. Sci. 2016, 57, 4255–4263. [Google Scholar] [CrossRef] [Green Version]
  53. Ku, C.A.; Hull, S.; Arno, G.; Vincent, A.; Carss, K.; Kayton, R.; Weeks, D.; Anderson, G.W.; Geraets, R.; Parker, C.; et al. Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration. JAMA Ophthalmol. 2017, 135, 749–760. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Khan, M.I.; Kersten, F.F.; Azam, M.; Collin, R.W.; Hussain, A.; Shah, S.T.; Keunen, J.E.; Kremer, H.; Cremers, F.P.; Qamar, R.; et al. CLRN1 mutations cause nonsyndromic retinitis pigmentosa. Ophthalmology 2011, 118, 1444–1448. [Google Scholar] [CrossRef] [PubMed]
  55. Xu, M.; Xie, Y.A.; Abouzeid, H.; Gordon, C.T.; Fiorentino, A.; Sun, Z.; Lehman, A.; Osman, I.S.; Dharmat, R.; Riveiro-Alvarez, R.; et al. Mutations in the Spliceosome Component CWC27 Cause Retinal Degeneration with or without Additional Developmental Anomalies. Am. J. Hum. Genet. 2017, 100, 592–604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Lam, B.L.; Zuchner, S.L.; Dallman, J.; Wen, R.; Alfonso, E.C.; Vance, J.M.; Pericak-Vance, M.A. Mutation K42E in dehydrodolichol diphosphate synthase (DHDDS) causes recessive retinitis pigmentosa. Adv. Exp. Med. Biol. 2014, 801, 165–170. [Google Scholar]
  57. Zelinger, L.; Banin, E.; Obolensky, A.; Mizrahi-Meissonnier, L.; Beryozkin, A.; Bandah-Rozenfeld, D.; Frenkel, S.; Ben-Yosef, T.; Merin, S.; Schwartz, S.B.; et al. A missense mutation in DHDDS, encoding dehydrodolichyl diphosphate synthase, is associated with autosomal-recessive retinitis pigmentosa in Ashkenazi Jews. Am. J. Hum. Genet. 2011, 88, 207–215. [Google Scholar] [CrossRef] [Green Version]
  58. Kuehlewein, L.; Schols, L.; Llavona, P.; Grimm, A.; Biskup, S.; Zrenner, E.; Kohl, S. Phenotypic spectrum of autosomal recessive retinitis pigmentosa without posterior column ataxia caused by mutations in the FLVCR1 gene. Graefes Arch. Clin. Exp. Ophthalmol. 2019, 257, 629–638. [Google Scholar] [CrossRef]
  59. Haer-Wigman, L.; Newman, H.; Leibu, R.; Bax, N.M.; Baris, H.N.; Rizel, L.; Banin, E.; Massarweh, A.; Roosing, S.; Lefeber, D.J.; et al. Non-syndromic retinitis pigmentosa due to mutations in the mucopolysaccharidosis type IIIC gene, heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT). Hum. Mol. Genet. 2015, 24, 3742–3751. [Google Scholar] [CrossRef]
  60. Xu, M.; Yang, L.; Wang, F.; Li, H.; Wang, X.; Wang, W.; Ge, Z.; Wang, K.; Zhao, L.; Li, H.; et al. Mutations in human IFT140 cause non-syndromic retinal degeneration. Hum. Genet. 2015, 134, 1069–1078. [Google Scholar] [CrossRef] [Green Version]
  61. Stone, E.M.; Cideciyan, A.V.; Aleman, T.S.; Scheetz, T.E.; Sumaroka, A.; Ehlinger, M.A.; Schwartz, S.B.; Fishman, G.A.; Traboulsi, E.I.; Lam, B.L.; et al. Variations in NPHP5 in patients with nonsyndromic leber congenital amaurosis and Senior-Loken syndrome. Arch. Ophthalmol. 2011, 129, 81–87. [Google Scholar] [CrossRef] [Green Version]
  62. Khan, K.N.; El-Asrag, M.E.; Ku, C.A.; Holder, G.E.; McKibbin, M.; Arno, G.; Poulter, J.A.; Carss, K.; Bommireddy, T.; Bagheri, S.; et al. Specific Alleles of CLN7/MFSD8, a Protein That Localizes to Photoreceptor Synaptic Terminals, Cause a Spectrum of Nonsyndromic Retinal Dystrophy. Investig. Ophthalmol. Vis. Sci. 2017, 58, 2906–2914. [Google Scholar] [CrossRef] [Green Version]
  63. Collison, F.T.; Xie, Y.A.; Gambin, T.; Jhangiani, S.; Muzny, D.; Gibbs, R.; Lupski, J.R.; Fishman, G.A.; Allikmets, R. Whole Exome Sequencing Identifies an Adult-Onset Case of Methylmalonic Aciduria and Homocystinuria Type C (cblC) with Non-Syndromic Bull’s Eye Maculopathy. Ophthalmic Genet. 2015, 36, 270–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Siemiatkowska, A.M.; van den Born, L.I.; van Hagen, P.M.; Stoffels, M.; Neveling, K.; Henkes, A.; Kipping-Geertsema, M.; Hoefsloot, L.H.; Hoyng, C.B.; Simon, A.; et al. Mutations in the mevalonate kinase (MVK) gene cause nonsyndromic retinitis pigmentosa. Ophthalmology 2013, 120, 2697–2705. [Google Scholar] [CrossRef] [PubMed]
  65. Chen, Z.Y.; Battinelli, E.M.; Fielder, A.; Bundey, S.; Sims, K.; Breakefield, X.O.; Craig, I.W. A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat. Genet. 1993, 5, 180–183. [Google Scholar] [CrossRef] [PubMed]
  66. Webb, T.R.; Parfitt, D.A.; Gardner, J.C.; Martinez, A.; Bevilacqua, D.; Davidson, A.E.; Zito, I.; Thiselton, D.L.; Ressa, J.H.; Apergi, M.; et al. Deep intronic mutation in OFD1, identified by targeted genomic next-generation sequencing, causes a severe form of X-linked retinitis pigmentosa (RP23). Hum. Mol. Genet. 2012, 21, 3647–3654. [Google Scholar] [CrossRef] [Green Version]
  67. Vincent, A.; Forster, N.; Maynes, J.T.; Paton, T.A.; Billingsley, G.; Roslin, N.M.; Ali, A.; Sutherland, J.; Wright, T.; Westall, C.A.; et al. OTX2 mutations cause autosomal dominant pattern dystrophy of the retinal pigment epithelium. J. Med. Genet. 2014, 51, 797–805. [Google Scholar] [CrossRef]
  68. Tee, J.J.; Smith, A.J.; Hardcastle, A.J.; Michaelides, M. RPGR-associated retinopathy: Clinical features, molecular genetics, animal models and therapeutic options. Br. J. Ophthalmol. 2016, 100, 1022–1027. [Google Scholar] [CrossRef]
  69. Riazuddin, S.A.; Iqbal, M.; Wang, Y.; Masuda, T.; Chen, Y.; Bowne, S.; Sullivan, L.S.; Waseem, N.H.; Bhattacharya, S.; Daiger, S.P.; et al. A splice-site mutation in a retina-specific exon of BBS8 causes nonsyndromic retinitis pigmentosa. Am. J. Hum. Genet. 2010, 86, 805–812. [Google Scholar] [CrossRef] [Green Version]
  70. Rivolta, C.; Sweklo, E.A.; Berson, E.L.; Dryja, T.P. Missense mutation in the USH2A gene: Association with recessive retinitis pigmentosa without hearing loss. Am. J. Hum. Genet. 2000, 66, 1975–1978. [Google Scholar] [CrossRef] [Green Version]
  71. Ehrenberg, M.; Weiss, S.; Orenstein, N.; Goldenberg-Cohen, N.; Ben-Yosef, T. The co-occurrence of rare non-ocular phenotypes in patients with inherited retinal degenerations. Mol. Vis. 2019, 25, 691–702. [Google Scholar]
  72. Ku, C.A.; Pennesi, M.E. The new landscape of retinal gene therapy. Am. J. Med. Genet. C Semin. Med. Genet. 2020, 184, 846–859. [Google Scholar] [CrossRef]
  73. Bach, G.; Webb, M.B.; Bargal, R.; Zeigler, M.; Ekstein, J. The frequency of mucolipidosis type IV in the Ashkenazi Jewish population and the identification of 3 novel MCOLN1 mutations. Hum. Mutat. 2005, 26, 591. [Google Scholar] [CrossRef] [PubMed]
  74. Ben-Yosef, T.; Ness, S.L.; Madeo, A.C.; Bar-Lev, A.; Wolfman, J.H.; Ahmed, Z.M.; Desnick, R.J.; Willner, J.P.; Avraham, K.B.; Ostrer, H.; et al. A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. N. Engl. J. Med. 2003, 348, 1664–1670. [Google Scholar] [CrossRef] [PubMed]
  75. Fedick, A.; Jalas, C.; Abeliovich, D.; Krakinovsky, Y.; Ekstein, J.; Ekstein, A.; Treff, N.R. Carrier frequency of two BBS2 mutations in the Ashkenazi population. Clin. Genet. 2014, 85, 578–582. [Google Scholar] [CrossRef] [PubMed]
  76. Ness, S.L.; Ben-Yosef, T.; Bar-Lev, A.; Madeo, A.C.; Brewer, C.C.; Avraham, K.B.; Kornreich, R.; Desnick, R.J.; Willner, J.P.; Friedman, T.B.; et al. Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. J. Med. Genet. 2003, 40, 767–772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Joensuu, T.; Hamalainen, R.; Yuan, B.; Johnson, C.; Tegelberg, S.; Gasparini, P.; Zelante, L.; Pirvola, U.; Pakarinen, L.; Lehesjoki, A.E.; et al. Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. Am. J. Hum. Genet. 2001, 69, 673–684. [Google Scholar] [CrossRef] [Green Version]
  78. Kyttala, M.; Tallila, J.; Salonen, R.; Kopra, O.; Kohlschmidt, N.; Paavola-Sakki, P.; Peltonen, L.; Kestila, M. MKS1, encoding a component of the flagellar apparatus basal body proteome, is mutated in Meckel syndrome. Nat. Genet. 2006, 38, 155–157. [Google Scholar] [CrossRef]
  79. Branham, K.; Schlegel, D.; Fahim, A.T.; Jayasundera, K.T. Genetic testing for inherited retinal degenerations: Triumphs and tribulations. Am. J. Med. Genet. C Semin. Med. Genet. 2020, 184, 571–577. [Google Scholar] [CrossRef]
  80. Mansfield, B.C.; Yerxa, B.R.; Branham, K.H. Implementation of a registry and open access genetic testing program for inherited retinal diseases within a non-profit foundation. Am. J. Med. Genet. C Semin. Med. Genet. 2020, 184, 838–845. [Google Scholar] [CrossRef]
  81. Stone, E.M.; Andorf, J.L.; Whitmore, S.S.; DeLuca, A.P.; Giacalone, J.C.; Streb, L.M.; Braun, T.A.; Mullins, R.F.; Scheetz, T.E.; Sheffield, V.C.; et al. Clinically Focused Molecular Investigation of 1000 Consecutive Families with Inherited Retinal Disease. Ophthalmology 2017, 124, 1314–1331. [Google Scholar] [CrossRef]
  82. Haer-Wigman, L.; van Zelst-Stams, W.A.; Pfundt, R.; van den Born, L.I.; Klaver, C.C.; Verheij, J.B.; Hoyng, C.B.; Breuning, M.H.; Boon, C.J.; Kievit, A.J.; et al. Diagnostic exome sequencing in 266 Dutch patients with visual impairment. Eur. J. Hum. Genet. 2017, 25, 591–599. [Google Scholar] [CrossRef]
Diagnostics 10 00779 g001 550
Figure 1. Systems and organs most commonly involved in syndromic IRDs.
Figure 1. Systems and organs most commonly involved in syndromic IRDs.
Diagnostics 10 00779 g001
Diagnostics 10 00779 g002 550
Figure 2. A Venn diagram showing the involvement of syndromic IRD genes in non-syndromic IRD phenotypes. CRD: cone–rod dystrophy; EVR: exudative vitreoretinopathy; LCA: Leber congenital amaurosis; MD: macular dystrophy; PD: pattern dystrophy; RD: retinal dystrophy; RP: retinitis pigmentosa.
Figure 2. A Venn diagram showing the involvement of syndromic IRD genes in non-syndromic IRD phenotypes. CRD: cone–rod dystrophy; EVR: exudative vitreoretinopathy; LCA: Leber congenital amaurosis; MD: macular dystrophy; PD: pattern dystrophy; RD: retinal dystrophy; RP: retinitis pigmentosa.
Diagnostics 10 00779 g002
Table
Table 1. Syndromic inherited retinal diseases (IRDs).
Table 1. Syndromic inherited retinal diseases (IRDs).
Syndrome
(MIM/Reference)		GeneInheritance *Main Ocular Phenotypes #Main Extra-Ocular Phenotypes
Abetalipoproteinemia; ABL (#200100)MTTPARRPFat malabsorption, neurodegeneration, acanthocytosis
Aicardi Syndrome; AIC (#304050)Xp22 abnormalitiesXLDChorioretinopathy, OA, microphthalmia, optic nerve coloboma, cataractCallosal agenesis, PGR, microcephaly, ID, skeletal anomalies, neoplasia
Alagille Syndrome 1; ALGS1 (#118450)JAG1AD Iris stromal hypoplasia, posterior embryotoxon, microcornea, anomalous optic disc, peripapillary retinal depigmentation, chorioretinopathy Liver disease, skeletal and renal involvement, characteristic facial features, ID, FTT
Alport Syndrome 1; ATS1
(#3010150)		COL4A5XLDFleck retinopathy, cataract, myopia, corneal abnormalitiesHL, renal disease
Alstrom Syndrome; ALMS (#203800)ALMS1ARCRD, MD, cataractDD, SS, obesity, HL, cardiac, skeletal, hepatic, renal and endocrine involvement
Alpha-Methylacyl-CoA Racemase Deficiency; AMACRD (#614307)AMACRARRPNeurodegeneration
Autoimmune Polyendocrine Syndrome, Type I, with or without Reversible Metaphyseal Dysplasia; APS1 (#240300)AIREAD, ARRP, keratopathy, keratoconjunctivitisMultiple autoantibodies, anemia, hepatic, gastrointestinal, dental, skin, hair and endocrine involvement, hypogonadism
Bardet–Biedl Syndrome; BBS
(#209900, #615981, #600151, #615982, #615983, #605231, #615984, #615985, #615986, #615987, #615988, #615989, #615990, #615991, 615992, #615993, #615994, #615995, #615996, #617119, #617406)
[7]		BBS1, BBS2, ARL6, BBS4, BBS5, MKKS, BBS7, TTC8, PTHB1, BBS10, TRIM32, BBS12, MKS1, CEP290, WDPCP, SDCCAG8, LZTFL1, BBIP1, IFT27, IFT74, C8ORF37, CEP164ARRP, strabismus, cataractID, SS, obesity, hypogonadism, renal disease, polydactyly
Cerebellar Atrophy with Pigmentary Retinopathy [8]MSTO1ARRDCerebellar atrophy, ID, PGR
Congenital Disorder of Glycosylation; CDG
(#212065, #617082, #613861, #608799, #300896)		PMM2, NUS1, DHDDS, DPM1, SLC35A2ARRPFTT, microcephaly, ID, neurodegeneration, cardiac, hepatic, gastrointestinal, renal and hematological involvement
Congenital Disorder of Glycosylation with Defective Fucosylation 2; CDGF2 (#618324)FCSKARMD, OA, strabismusFTT, ID, hypotonia, neurodegeneration, gastrointestinal anomalies
Cranioectodermal Dysplasia 4; CED4 (#614378)WDR19ARRPSkeletal anomalies, SS, respiratory, hepatic and renal involvement
Ceroid Lipofuscinosis, Neuronal; CLN
(#256730, #204500, #204200, #256731, #601780, #610951, #600143, #610127, #614706)		PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, GRNARRP, CRD, OAMicrocephaly, ID, neurodegeneration
Cohen Syndrome; COH1 (#216550)VPS13BARRD, OA, strabismus, high myopiaID, DD, microcephaly, SS, obesity, skeletal, cardiac, hematological and endocrine involvement
Coenzyme Q10 Deficiency, Primary, 1; COQ10D1 (#607426)COQ2ARRPID, cerebellar atrophy, HL, cardiac, hepatic, renal and muscular involvement
Combined Oxidative Phosphorylation Deficiency 29; COXPD29 (#616811)TXN2ARRD, OAMicrocephaly, hypotonia, DD, ID, neurodegeneration
Charcot–Marie–Tooth Disease, X-linked recessive, 5; CMTX5 (#311070)PRPS1XLRRP, OAPeripheral neuropathy, HL
Cone–Rod Dystrophy and Hearing Loss 1; CRDHL1 (#617236)CEP78ARCRDHL
Cockayne Syndrome; CS (#216400, #133540)ERCC8, ERCC6ARRD, OA, cataract, strabismusIUGR, PGR, microcephaly, ID, neurodegeneration, HL, renal, skeletal and skin involvement
Cystinosis, Nephropathic; CTNS
(#219800, #219900)		CTNSARRD, corneal crystalsRenal disease, neurodegeneration, skeletal and endocrine anomalies
Danon Disease (#300257)LAMP2XLDRDCardiac disease, myopathy, ID
Diabetes and Deafness, Maternally Inherited; MIDD (#520000)MTTL1, MTTE, MTTK, mitochondrial DNA rearrangementsMiRD, MD, ophthalmoplegiaHL, cardiac and neurological anomalies, diabetes mellitus
Dyskeratosis Congenita, Autosomal Dominant 3; DKCA3 (#613990)TINF2ADRD, blockage of lacrimal ductsIUGR, SS, microcephaly, ID, HL, respiratory, skin, skeletal and hematological involvement, neoplasia
Hypobetalipoproteinemia, Familial, 1; FHBL1 (#615558)APOBARRPFat malabsorption, neurodegeneration, acanthocytosis
Hypobetalipoproteinemia, Acanthocytosis, Retinitis Pigmentosa and Pallidal Degeneration; HARP (#607236)PANK2ARRPFat malabsorption, neurodegeneration, acanthocytosis
Hypotrichosis, Congenital, with Juvenile Macular Dystrophy; HJMD (#601553)CDH3ARMDHypotrichosis
Hermansky–Pudlak Syndrome; HPS
(#614072, #614073, #614077)		HPS3, HPS4, BLOC1S3ARHypopigmentation of retina and choroid, foveal hypoplasia, nystagmus, iris transillumination Skin and hair hypopigmentation, bleeding diathesis
Hyper-IgD Syndrome; HIDS (#260920)MVKARRPHematological anomalies, gastrointestinal and skeletal involvement, periodic fever
Hyperoxaluria, Primary, Type I; HP1 (#259900)AGXTARRD, OARenal disease, dental, cardiovascular and skin involvement, peripheral neuropathy
Intellectual Developmental Disorder and Retinitis Pigmentosa; IDDRP (#618195)SCAPERARRP, MD, cataract ID, skeletal abnormalities, male sterility
Jalili Syndrome (#217080)CNNM4ARCRDAmelogenesis imperfecta
Joubert Syndrome; JBTS
(#213300, #608091, #608629, #610188, #610688, #611560, #612291, #612285, #614464, #614465, #614844, #614970, #615636, #615665, #616781, #617121, #617562, #617622, #618161, #300804)		INPP5E, TMEM216, AHI1, CEP290, TMEM67, RPGRIP1L, ARL13B, CC2D2A, CEP41, TMEM138, ZNF423, TMEM231, CSPP1, PDE6D, CEP104, MKS1, TMEM107, ARMC9, ARL3ARRD, chorioretinal coloboma, optic nerve coloboma, microphthalmia, oculomotor apraxia, esotropia, ptosisBrain structural anomalies, FTT, macrocephaly, ID, neurodegeneration, genitourinary, hepatic, respiratory and skeletal involvement
OFD1XLR
Kearns–Sayre Syndrome; KSS (#530000)Mitochondrial DNA deletionsMiRD, ophthalmoplegiaSS, microcephaly, neurodegeneration, cardiac, renal and endocrine involvement
Laurence–Moon Syndrome; LNMS (#245800)PNPLA6ARChorioretinal degenerationID, neurodegeneration, genitourinary abnormalities
Leber Congenital Amaurosis with Early-Onset Deafness; LCAEOD (#617879)TUBB4BADLCAHL
Lipodystrophy, familial partial, type7; FPLD7 (#606721)CAV1ADRD, cataractLack of facial fat, orthostatic hypotension, neurological and skin involvement
Methylmalonic Aciduria and Homocystinuria, cblC type; MAHCC (#277400)MMACHCARRP, CRDFTT, microcephaly, ID, neurodegeneration, renal and hematological involvement
Mevalonic Aciduria; MEVA (#610377)MVKARRP, OA, cataractFTT, DD, neurodegeneration, spleen, hepatic, skeletal, skin and hematological involvement
Microcephaly and Chorioretinopathy, autosomal recessive; MCCRP (#251270, #616171, #616335)TUBGCP6, PLK4, TUBGCP4ARChorioretinopathy, OA, microphthalmia, microcornea, cataractIUGR, microcephaly, brain structural anomalies, DD, ID, neurodegeneration, SS
Microcephaly with or without Chorioretinopathy, Lymphedema or Mental Retardation; MCLMR (#152950)KIF11ADChorioretinopathy, myopia, hypermetropia, corneal opacity, microcornea, microphthalmia, cataractMicrocephaly, ID, neurodegeneration, lymphedema
Microphthalmia, Syndromic 5; MCOPS5 (#610125)OTX2ADRD, microphthalmia, anophthalmia, optic nerve hypoplasia or agenesis, microcornea, cataractBrain structural anomalies, hypotonia, pituitary dysfunction, DD, SS, cleft palate, abnormal genitalia, joint laxity
Mitochondrial Complex II Deficiency (#252011)SDHA, SDHD, SDHAF1ARRD, OA, ptosis, ophthalmoplegiaSS, cardiac, skeletal, muscular and neurological involvement
Mitochondrial Complex IV Deficiency (#220110)APOPT1, COA3, COX6A2, COX6B1, COX8A, COX10, COX14, COX20, PET100, TACO1ARRD, OA, ptosisFTT, brain structural anomalies, ID, HL, cardiac, respiratory, hepatic, renal and muscular involvement
Mucolipidosis III alpha/beta; MLIII A/B (#252600)GNPTABARRD, corneal cloudingNeurodegeneration, ID, SS, coarse facies, skeletal, cardiac and skin involvement
Mucolipidosis IV; ML4 (#252650)MCOLN1ARRD, OA, corneal disease, strabismusMicrocephaly, ID, neurodegeneration
Mucopolysaccharidosis; MPS
(#309900, #252930, #607014, #253000, #253010)		IDSXLRRP, ptosis, corneal cloudingNeurodegeneration, ID, SS, coarse facies, HL, skeletal, cardiac, respiratory, hepatic, gastrointestinal and skin involvement
HGSNAT, IDUA, GALN5, GLB1AR
Nephronophthisis 15; NPHP15
(#614845)		CEP164ARLCARenal disease
Neurodegeneration with Brain Iron Accumulation 1; NBIA1 (#234200)PANK2ARRD, OA, eyelid apraxiaNeurodegeneration, gastrointestinal, skeletal, skin and muscular involvement
Neuropathy, Ataxia and Retinitis Pigmentosa; NARP (#551500)MTATP6MiRPNeurodegeneration, ataxia
Norrie Disease; ND (#310600) NDPXLRRetinal dysgenesis, retinal dysplasia, OA, microphthalmia, vitreous atrophy, corneal opacities, iris atrophy, cataractHL, ID, neurodegeneration
Oculoauricular Syndrome; OCACS (#612109)HMX1ARRP, microphthalmia, microcornea, cataract, microphakia, sclerocornea, increased intraocular pressure External ear abnormalities
Orofaciodigital Syndrome XVI; OFD16 (#617563)TMEM107ARRD, oculomotor apraxia, ptosisFacial anomalies, breathing abnormalities, polydactyly, hypotonia, ID, neurological anomalies
Oliver–McFarlane Syndrome; OMCS (#275400)PNPLA6ARChorioretinopathy, OASS, ID, neurodegeneration, obesity, male external genitalia abnormalities, endocrine anomalies
Peroxisomal Acyl-CoA Oxidase Deficiency (#264470)ACOX1ARRD, OA, strabismusNeurodegeneration, ID, HL, liver disease
Peroxisome Biogenesis Disorder; PBD (#214100, #614866, #601539, #234580, #614879, #266510)PEX1, PEX2, PEX5, PEX6, PEX7, PEX12ARRD, OA, corneal clouding, cataractFTT, neurodegeneration, ID, HL, dental, cardiac, hepatic, genitourinary and skeletal involvement
Posterior Column Ataxia with Retinitis Pigmentosa; AXPC1 (#609033)FLVCR1ARRP, OAPosterior column ataxia, neurodegeneration, gastrointestinal and skeletal involvement
Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa and Cataract; PHARC (#612674)ABHD12ARRP, OA, cataractAtaxia, neurodegeneration, HL
Pseudoxanthoma Elasticum; PXE (#264800)ABCC6ARRD, MD, choroidal neovascularizationSkin lesions, cardiovascular disease, gastrointestinal and genitourinary involvement
Refsum Disease, classic (#266500)PHYHARRPNeurodegeneration, ataxia, HL, anosmia, cardiac, skeletal and skin involvement
Retinal Dystrophy, Iris Coloboma and Comedogenic Acne Syndrome; RDCCAS (#615147)RPB4ARRD, coloboma of the iris, displacement of the pupil, microcornea, cataractComedogenic acne
Retinal Dystrophy and Iris Coloboma with or without Cataract; RDICC (#616722)MIR204ADRD, coloboma of the iris, congenital cataract
Retinal Dystrophy, Juvenile Cataracts and Short Stature Syndrome; RDJCSS (#616108)RDH11ARRD, juvenile cataractsSS, DD, ID, dental anomalies
Retinal Dystrophy and Obesity; RDOB (#616188)TUBARRDObesity
Revesz Syndrome (#268130)TINF2ADRDIUGR, brain structural anomalies, neurodegeneration, ID, aplastic anemia, skin, hair and nail abnormalities
Retinitis Pigmentosa–Deafness Syndrome (#500004)MTTS2MiRPHL
Retinitis Pigmentosa and Erythrocytic Microcytosis; RPEM (#616959)TRNT1ARRPErythrocytic microcytosis and additional hematologic abnormalities
Retinitis Pigmentosa, Hypopituitarism, Nephronophtisis and mild Skeletal Dysplasia; RHYNS (#602152)TMEM67ARRPHypopituitarism, renal disease, skeletal anomalies, HL
Retinitis Pigmentosa 82 with or without Situs Inversus; RP82 (#615434)ARL2BPARRPSitus inversus, male infertility
Retinitis Pigmentosa with or without Skeletal Anomalies; RPSKA (#250410)CWC27ARRPSS, skeletal anomalies, ID
Retinitis Pigmentosa, X-linked and Sinorespiratory Infections, with or without Deafness (#300455)RPGRXLRPRecurrent respiratory infections, HL
Senior–Løken Syndrome; SLSN
(#266900, #606996, #609254, #610189, #613615, #616307, #616629)		NPHP1, NPHP4, IQCB1, CEP290, SDCCAG8, WDR19, TRAF3IP1ARRP, LCARenal disease
Short Stature, Hearing Loss, Retinitis Pigmentosa and Distinctive Facies; SHRF (#617763)EXOSC2ARRP, corneal dystrophy, glaucoma, strabismusSS, facial anomalies, HL, neurodegeneration, DD, ID
Sideroblastic Anemia with B-cell Immunodeficiency, Periodic Fevers and Developmental Delay; SIFD (#616084)TRNT1ARRPSideroblastic anemia, immunodeficiency, growth retardation, DD, periodic fever, HL, neurological, cardiac and renal involvement
Spondylometaphyseal Dysplasia with Cone–Rod Dystrophy; SMDCRD (#608940)PCYT1AARCRDSkeletal anomalies, PGR
Spondylometaphyseal Dysplasia, Axial; SMDAX (#602271)CFAP410ARRP, CRD, OASkeletal anomalies, respiratory disease, reduced sperm motility
Short-Rib Thoracic Dysplasia 9 with or without Polydactyly; SRTD9 (#266920)IFT140ARRPSkeletal anomalies,
renal disease, ID
Thiamine-Responsive Megaloblastic Anemia Syndrome; TRMA (#249270)SLC19A2AROA, RDMegaloblastic anemia, diabetes mellitus, HL
Usher Syndrome; USH
(#276900, #276904, #601067, #602083, #606943, #614869, #276901, #605472, #611383, #276902, #614504)		MYO7A, USH1C, CDH23, PCDH15, USH1G, CIB2, USH2A, ADGRV1, WHRN, CLRN1, HARS1ARRPHL, vestibular dysfunction
Wolfram Syndrome 1, WFS1 (#222300)WFS1AROA, RDDiabetes mellitus, diabetes insipidus, HL, neurodegeneration, genitourinary and neurologic involvement
White–Sutton Syndrome, WHSUS (#616364)POGZADRP, OA, cortical blindnessDD, characteristic facial features, hypotonia, HL, joint laxity, gastrointestinal anomalies
Xeroderma Pigmentosum, group B; XPB (#610651)ERCC3ARRD, OA, micropathalmiaNeoplasia, skin anomalies, SS, microcephaly, HL, ID, brain structural anomalies, neurodegeneration
* AD, autosomal dominant; AR, autosomal recessive; Mi, mitochondrial; XL, X-linked; XLD, X-linked dominant; XLR, X-linked recessive. # CRD, cone–rod dystrophy; LCA, Leber congenital amaurosis; MD, macular dystrophy; OA, optic atrophy; RD, retinal dystrophy; RP, retinitis pigmentosa. DD, developmental delay; FTT, failure to thrive; HL, hearing loss; ID, intellectual disability; IUGR, intrauterine growth restriction; PGR, postnatal growth retardation; SS, short stature.
Table
Table 2. Genes underlying both syndromic and non-syndromic IRDs.
Table 2. Genes underlying both syndromic and non-syndromic IRDs.
GeneSyndromic IRDNon-Syndromic IRD (MIM)Reference
ABHD12PHARCarRP[40]
AHI1JBTS3arRP[41]
ALMS1ALMSarCRD, arEORD[42]
ARL2BPRP with situs inversusarRP (#615434)[43,44]
ARL3JBTS35adRP (#618173)[45]
ARL6BBS3arRP (#613575)[46]
BBS2BBS2arRP (#616562)[47]
C8ORF37BBS21arCRD, arRP (#614500)[48]
CC2D2AJBTS9, MKS6arRP[49]
CEP290BBS14, JBTS5, MKS4, SLSN6arLCA (#611755)[50]
CFAP410SMDAXarRD with or without macular staphyloma (#617547)[51,52]
CLN3CLN3arRP[53]
CLRN1USH3AarRP (#614180)[54]
CWC27RPSKAarRP (#250410)[55]
DHDDSCDG1BBarRP (#613861)[56,57]
FLVCR1PCARParRP[58]
HGSNATMPS3CarRP (#616544)[59]
IFT140SRTD9 with/without polydactylyarRP (#617781)[60]
IQCB1SLSN5arLCA[61]
MFSD8CLN7arMD (#616170), arRD[62]
MMACHCMAHCCarMD[63]
MVKHIDS, MEVAarRP[64]
NDPNDXL EVR (#305390)[65]
OFD1JBTS10XL RP (#300424)[66]
OTX2RD with pituitary dysfunctionadPD (#610125)[67]
RPGRRP, sinorespiratory infections and deafnessXL CRD (#304020), XL MD (#300834), XL RP (#300029)[68]
TTC8BBS8arRP (#613464)[69]
USH2AUSH2AarRP (#613809)[70]
ALMS: Alstrom syndrome; ar: autosomal recessive; ad: autosomal dominant; BBS: Bardet–Biedl syndrome; CDG: congenital disorder of glycosylation; CLN: ceroid lipofuscinosis neuronal; CRD: cone–rod dystrophy; EORD: early-onset retinal degeneration; EVR: exudative vitreoretinopathy; HIDS: hyper-IgD syndrome; JBTS: Joubert syndrome; LCA: Leber congenital amaurosis; MAHCC: methylmalonic aciduria and homocystinuria, cblC type; MD: macular dystrophy; MEVA: mevalonic aciduria; MKS: Meckel syndrome; MPS: mucopolysaccharidosis; ND: Norrie disease; PCARP: posterior column ataxia with retinitis pigmentosa; PD: pattern dystrophy; PHARC: polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract; RD: retinal dystrophy; RP: retinitis pigmentosa; RPSKA: retinitis pigmentosa with skeletal anomalies; SLSN: Senior–Løken syndrome; SMDAX: spondylometaphyseal dysplasia axial; SRTD: short-rib thoracic dysplasia; USH: Usher syndrome; XL: X-linked.

Share and Cite

MDPI and ACS Style

Tatour, Y.; Ben-Yosef, T. Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic Aspects. Diagnostics 2020, 10, 779. https://doi.org/10.3390/diagnostics10100779

AMA Style

Tatour Y, Ben-Yosef T. Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic Aspects. Diagnostics. 2020; 10(10):779. https://doi.org/10.3390/diagnostics10100779

Chicago/Turabian Style

Tatour, Yasmin, and Tamar Ben-Yosef. 2020. "Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic Aspects" Diagnostics 10, no. 10: 779. https://doi.org/10.3390/diagnostics10100779

APA Style

Tatour, Y., & Ben-Yosef, T. (2020). Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic Aspects. Diagnostics, 10(10), 779. https://doi.org/10.3390/diagnostics10100779

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop